{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:41:01Z","timestamp":1772012461772,"version":"3.50.1"},"reference-count":5,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2001]]},"abstract":"<jats:p>&lt;i&gt;Objectives:&lt;\/i&gt; Patients with symptomatic bladder outlet obstruction and moderately enlarged prostates can receive durable relief from finasteride. However, the delayed onset of action has led many clinicians to prescribe an \u03b1-blocker in addition to finasteride early in therapy for more rapid symptom relief. Our goal was to determine when to discontinue the \u03b1-blocker in this group of patients. &lt;i&gt;Methods:&lt;\/i&gt; We enrolled 100 consecutive men with an estimated prostate size of &gt;40 g and an AUA symptom score of \u226720, who reported an initially favorable response to combination therapy with 5 mg finasteride and 2 mg doxazosin daily. The average symptom score reduction at 1 month was 3.3. We discontinued the doxazosin at 3, 6, 9, or 12 months, while continuing finasteride, then reevaluated patients 1 month later to determine if the patients reported any worsening of symptoms. &lt;i&gt;Results:&lt;\/i&gt; Twenty-five patients discontinued doxazosin at 3 months. Five (20%) were successfully discontinued, reporting no change in symptom score. Twenty reported worsening symptoms. Twenty-five patients discontinued doxazosin at 6 months. Twelve (48%) were successfully discontinued, reporting no change in symptom scores. Thirteen (52%) reported worsening symptoms. Twenty-five patients discontinued doxazosin at 9 months. Twenty-one (84%) were successfully discontinued, reporting no change in symptom scores. Four (16%) reported worsening symptoms. Twenty-five patients discontinued doxazosin at 12 months. Twenty-one (84%) were successfully discontinued, reporting no change in symptom scores. Four (16%) reported worsening symptoms. &lt;i&gt;Conclusion:&lt;\/i&gt; Patients with symptomatic bladder outlet obstruction and moderately enlarged prostates who are placed initially on combination therapy using finasteride and an \u03b1-blocker are likely to tolerate discontinuation of the \u03b1-blocker after 9 months of combination therapy.<\/jats:p>","DOI":"10.1159\/000056576","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T19:06:20Z","timestamp":1050433580000},"page":"84-88","source":"Crossref","is-referenced-by-count":12,"title":["Discontinuation of Alpha-Blockade after Initial Treatment with Finasteride and Doxazosin for Bladder Outlet Obstruction"],"prefix":"10.1159","volume":"66","author":[{"given":"Kelly C.","family":"Baldwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip C.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Harkaway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2001,2,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90543-X"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000019566"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199802263380901"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608223350801"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000030217"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/56576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/56576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:49:20Z","timestamp":1745470160000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000056576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2001,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000056576","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001]]}}}